Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylergonovine vs progesterone vs expectant management for retained products of pregnancy
IRCT20260706070080N1Phase 3Completed
- Sponsor
- Sabzevar University of Medical Sciences
- Start
- Sep 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of medroxyprogesterone acetate and methylergometrine in retained placenta (3 arms), sponsored by Sabzevar University of Medical Sciences. Primary endpoints: Retained products of conception, Infection leading to hospitalization and 2 more. Started Sep 2026; status: completed.
02
Drugs
medroxyprogesterone acetatemethylergometrine
03
Conditions
retained placenta
Beyond the preview
Go deeper on IRCT20260706070080N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260706070080N1.